A 48-year-old man who underwent a deceased-donor kidney transplant 3 years ago is evaluate… — USMLE Step 3

A 48-year-old man who underwent a deceased-donor kidney transplant 3 years ago is evaluated in the clinic. He reports a 3-day history of a white coating in his mouth. He denies dysphagia, odynophagia, or fever. His current maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and prednisone. His allograft function has been stable with a baseline serum creatinine of $1.2\text{ mg/dL}$ . Today, his temperature is $37.0^\circ\text{C}$ ( $98.6^\circ\text{F}$ ). Physical examination reveals adherent white plaques on the buccal mucosa and tongue that can be easily scraped off. Laboratory studies obtained today show a serum creatinine of $1.3\text{ mg/dL}$ and a tacrolimus trough level of $6.5\text{ ng/mL}$ (target: $5-8\text{ ng/mL}$ ). The physician diagnoses oropharyngeal candidiasis and plans to prescribe a 14-day course of oral fluconazole. The patient also mentions he forgot to get his annual influenza vaccine and requests it during this visit. Which of the following is the most appropriate next step in the management of this patient?

A
Maintain the current tacrolimus dose and administer the inactivated influenza vaccine
B
Preemptively increase the tacrolimus dose and administer the live-attenuated influenza vaccine
Preemptively reduce the tacrolimus dose and administer the inactivated influenza vaccineAnswer
D
Temporarily discontinue tacrolimus until the serum creatinine returns to $1.2\text{ mg/dL}$
E
Delay fluconazole initiation and perform an upper gastrointestinal endoscopy

Answer

The most appropriate next step is to preemptively reduce the tacrolimus dose and administer the inactivated influenza vaccine.

The correct answer requires synthesizing two crucial aspects of outpatient management in a transplant recipient: drug interaction monitoring and preventive care. First, tacrolimus is a calcineurin inhibitor primarily metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) system. Fluconazole is a potent inhibitor of CYP3A4. Initiating fluconazole will rapidly decrease the clearance of tacrolimus, leading to supratherapeutic blood levels that cause acute nephrotoxicity and neurotoxicity. Therefore, standard of care dictates a preemptive reduction of the tacrolimus dose (usually by 25% to 50%) with close monitoring of trough levels a few days later. Second, the patient is requesting his annual influenza vaccine. Solid organ transplant recipients should receive the annual inactivated influenza vaccine. Live-attenuated vaccines (like the intranasal influenza vaccine) are strictly contraindicated due to the risk of unchecked vaccine-strain viral replication.

Step-by-Step Solution

Evaluate the planned pharmacotherapy (fluconazole) against the patient's current regimen (tacrolimus).

Identify a major drug-drug interaction: fluconazole is a strong CYP3A4 inhibitor, and tacrolimus is a CYP3A4 substrate.

Recognizing interactions is critical in transplant patients to prevent severe toxicity or graft rejection.

Determine the necessary dose adjustment for tacrolimus.

The tacrolimus dose must be preemptively reduced (typically by 25-50%) and trough levels monitored closely.

CYP3A4 inhibition will rapidly increase tacrolimus blood levels, risking nephrotoxicity and neurotoxicity if the dose is left unchanged.

Evaluate the patient's request for an influenza vaccine in the context of his immunosuppression.

Determine that the inactivated influenza vaccine is indicated and safe, while the live-attenuated version is contraindicated.

Immunosuppressed patients are at high risk for severe influenza complications but can develop unchecked vaccine-strain infections from live vaccines.

Key Concept

Pharmacokinetic monitoring of CYP3A4 substrates (tacrolimus) when initiating inhibitors (fluconazole), and safe vaccine administration in transplant recipients.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic